| Year |
Citation |
Score |
| 2023 |
Ruiz-Saenz A, Atreya CE, Wang C, Pan B, Dreyer CA, Brunen D, Prahallad A, Muñoz DP, Ramms DJ, Burghi V, Spassov DS, Fewings E, Hwang YC, Cowdrey C, Moelders C, et al. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF colorectal tumors. Nature Cancer. PMID 36759733 DOI: 10.1038/s43018-022-00508-5 |
0.566 |
|
| 2022 |
Fidelman N, Atreya CE, Griffith M, Milloy MA, Carnevale J, Cinar P, Venook AP, Van Loon K. Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with Y resin microspheres for chemo-refractory colorectal liver metastases. Bmc Cancer. 22: 1307. PMID 36514060 DOI: 10.1186/s12885-022-10401-0 |
0.348 |
|
| 2020 |
Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, et al. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001994. PMID 33356422 DOI: 10.1200/Jco.2017.35.4_Suppl.520 |
0.44 |
|
| 2020 |
Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nature Reviews. Clinical Oncology. PMID 32632268 DOI: 10.1038/S41571-020-0392-0 |
0.376 |
|
| 2020 |
Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, et al. BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32047001 DOI: 10.1158/1078-0432.Ccr-19-3579 |
0.381 |
|
| 2020 |
Fidelman N, Atreya C, Griffith M, Milloy A, Carnevale J, Cinar P, Venook A, Van Loon K. 3:54 PM Abstract No. 243 Phase I Prospective Trial of TAS-102 (trifluride and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases Journal of Vascular and Interventional Radiology. 31: S109. DOI: 10.1016/J.Jvir.2019.12.287 |
0.328 |
|
| 2020 |
Savoie M, Paciorek A, Van Blarigan E, Smith J, Laffan A, Zhang L, Levin A, Kenfield S, Anwar M, Atreya C, Venook A, Van Loon K, Rowen T. 006 Sexual Function in Women after Treatment for Colorectal Cancer and Anal Cancer The Journal of Sexual Medicine. 17: S221. DOI: 10.1016/J.Jsxm.2020.04.242 |
0.316 |
|
| 2018 |
Le D, Kavan P, Kim T, Burge M, Van Cutsem E, Hara H, Boland P, Van Laethem J, Geva R, Taniguchi H, Crocenzi T, Sharma M, Atreya C, Diaz L, Liang L, et al. Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability-high (MSI-H) colorectal cancer: KEYNOTE-164. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v107. PMID 32176999 DOI: 10.1093/Annonc/Mdy149.020 |
0.371 |
|
| 2018 |
Ursem C, Atreya CE, Van Loon K. Emerging treatment options for -mutant colorectal cancer. Gastrointestinal Cancer : Targets and Therapy. 8: 13-23. PMID 29628780 DOI: 10.2147/GICTT.S125940 |
0.466 |
|
| 2018 |
Corcoran RB, Andre T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discovery. PMID 29431699 DOI: 10.1158/2159-8290.Cd-17-1226 |
0.39 |
|
| 2018 |
Kelley RK, Mitchell E, Behr S, Hwang J, Keenan B, Cheung A, Gordan JD, Ko AH, Cinar P, Atreya CE, Van Loon K, Weber T, Ngo Z, Quandt ZE, Liu C, et al. Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC). Journal of Clinical Oncology. 36: 386-386. DOI: 10.1200/JCO.2018.36.4_SUPPL.386 |
0.594 |
|
| 2018 |
Kelley RK, Mitchell E, Behr S, Hwang J, Keenan B, Umetsu SE, Gordan JD, Ko AH, Cinar P, Atreya CE, Van Loon K, Weber T, Ngo Z, Quandt ZE, Liu C, et al. Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses. Journal of Clinical Oncology. 36: 4087-4087. DOI: 10.1200/JCO.2018.36.15_SUPPL.4087 |
0.589 |
|
| 2017 |
Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, et al. Genomic landscape of cell-free DNA in patients with colorectal cancer. Cancer Discovery. PMID 29196463 DOI: 10.1158/2159-8290.Cd-17-1009 |
0.346 |
|
| 2017 |
Rajaram S, Heinrich LE, Gordan JD, Avva J, Bonness KM, Witkiewicz AK, Malter JS, Atreya CE, Warren RS, Wu LF, Altschuler SJ. Sampling strategies to capture single-cell heterogeneity. Nature Methods. PMID 28869755 DOI: 10.1038/Nmeth.4427 |
0.54 |
|
| 2017 |
Parikh A, Atreya C, Korn WM, Venook AP. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 3-8. PMID 28040715 DOI: 10.6004/Jnccn.2017.0002 |
0.48 |
|
| 2017 |
Cantino L, Ursem C, Ritchie C, Rabow M, Atreya C, Bischoff K. Symptom Burden in Patients Initiating Treatment for Metastatic Colorectal Cancer (SA527B) Journal of Pain and Symptom Management. 53: 408. DOI: 10.1016/J.Jpainsymman.2016.12.207 |
0.341 |
|
| 2016 |
Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, et al. Radioembolization with (90)Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. Journal of Gastrointestinal Oncology. 7: 860-874. PMID 28078110 DOI: 10.1016/J.Jvir.2014.12.511 |
0.36 |
|
| 2016 |
Atreya CE, Greene C, McWhirter RM, Ikram NS, Allen IE, Van Loon K, Venook AP, Yeh BM, Behr SC. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 1536-1543. PMID 27956538 |
0.395 |
|
| 2016 |
Corcoran R, André T, Yoshino T, Bendell J, Atreya C, Schellens J, Ducreux M, McRee A, Siena S, Middleton G, Gordon M, Humblet Y, Muro K, Elez E, Yaeger R, et al. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC) Annals of Oncology. 27: vi150. DOI: 10.1093/Annonc/Mdw370.04 |
0.33 |
|
| 2015 |
Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26392102 DOI: 10.1200/Jco.2015.63.2471 |
0.373 |
|
| 2015 |
Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: refining the patient population. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 682-5. PMID 25584005 DOI: 10.1200/Jco.2014.58.9325 |
0.306 |
|
| 2015 |
Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, et al. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. International Journal of Cancer. Journal International Du Cancer. 136: 1967-75. PMID 25242168 DOI: 10.1002/Ijc.29225 |
0.414 |
|
| 2015 |
Kopetz S, McDonough S, Morris VK, Lenz H, Magliocco AM, Atreya CE, Diaz LA, Allegra CJ, Lieu CH, Eckhardt SG, Semrad TJ, Kaberle K, Guthrie K, Hochster HS. S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 33: TPS790-TPS790. DOI: 10.1200/Jco.2015.33.3_Suppl.Tps790 |
0.448 |
|
| 2015 |
Kelley RK, Nimeiri HS, Gordan JD, Hwang J, McWhirter RM, Kanakamedala A, Atreya CE, Kulik L, Kircher S, Mulcahy MF, Benson AB, Venook AP. Phase II trial of temsirolimus (TEM) plus sorafenib (SOR) in hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 33: TPS501-TPS501. DOI: 10.1200/JCO.2015.33.3_SUPPL.TPS501 |
0.63 |
|
| 2015 |
Abou-Alfa GK, Mayer RJ, Cosgrove D, Capanu M, Choti MA, Atreya CE, Ang C, Kelley RK, Do RKG, Gordan JD, Zhu AX, Ly M, Nolan P, Lubin L, Harding JJ, et al. Randomized phase II study of everolimus (E), leuprolide + letrozole (LL), and E + LL (ELL) in patients (pts) with unresectable fibrolamellar carcinoma (FLC). Journal of Clinical Oncology. 33: e15149-e15149. DOI: 10.1200/Jco.2015.33.15_Suppl.E15149 |
0.579 |
|
| 2015 |
Atreya CE, Van Cutsem E, Bendell JC, Andre T, Schellens JHM, Gordon MS, McRee AJ, O'Dwyer PJ, Muro K, Tabernero J, van Geel R, Sidhu R, Greger JG, Rangwala FA, Motwani M, et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 33: 103-103. DOI: 10.1200/Jco.2015.33.15_Suppl.103 |
0.416 |
|
| 2015 |
Van Cutsem E, Atreya C, André T, Bendell J, Schellens J, Gordon M, McRee A, Yoshino T, Muro K, ODwyer P, Tabernero J, Middleton G, Ducreux M, van Geel R, Sidhu R, et al. LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) Annals of Oncology. 26: iv119. DOI: 10.1093/Annonc/Mdv262.07 |
0.462 |
|
| 2014 |
Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 33: 1590-600. PMID 23542178 DOI: 10.1038/Onc.2013.92 |
0.729 |
|
| 2014 |
Atreya CE, Watters J, Rowley S, Lee JS, Iartchouk O, Light M, Warren RS, Venook AP. Molecular epidemiology of RAS/RAF-mutant colorectal cancer metastases. Journal of Clinical Oncology. 32: 470-470. DOI: 10.1200/JCO.2014.32.3_SUPPL.470 |
0.35 |
|
| 2014 |
Corcoran RB, Atreya CE, Falchook GS, Infante JR, Hamid O, Messersmith WA, Daud A, Kwak EL, Ryan D, Kurzrock R, Sun P, Cunningham EA, Orford KW, Motwani M, Bai Y, et al. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis. Journal of Clinical Oncology. 32: 3517-3517. DOI: 10.1200/Jco.2014.32.15_Suppl.3517 |
0.397 |
|
| 2014 |
Bendell JC, Atreya CE, André T, Tabernero J, Gordon MS, Bernards R, Van Cutsem E, Tejpar S, Sidhu R, Go WY, Allred A, Motwani M, Suttle BB, Wu Y, Hoos A, et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). Journal of Clinical Oncology. 32: 3515-3515. DOI: 10.1200/Jco.2014.32.15_Suppl.3515 |
0.434 |
|
| 2013 |
Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, Warren RS. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Medicine. 2: 496-506. PMID 24156022 DOI: 10.1002/Cam4.97 |
0.496 |
|
| 2013 |
Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5777-87. PMID 23983256 DOI: 10.1158/1078-0432.Ccr-13-0351 |
0.358 |
|
| 2013 |
Corcoran RB, Falchook GS, Infante JR, Hamid O, Messersmith WA, Daud A, Kwak EL, Ryan DP, Kurzrock R, Atreya CE, Luan J, Sun P, Schaeffer M, Motwani M, Bleam MR, et al. Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC). Journal of Clinical Oncology. 31: 3507-3507. DOI: 10.1200/Jco.2013.31.15_Suppl.3507 |
0.323 |
|
| 2012 |
Atreya CE, Warren RS, Niedzwiecki D, Mayer RJ, Goldberg RM, Compton CC, Zuraek M, Bergsland EK, Ye C, Weinberg VK, Bertagnolli MM. A novel interaction of genotype, gender, and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 452. PMID 27983199 DOI: 10.1200/jco.2012.30.4_suppl.452 |
0.362 |
|
| 2012 |
Ducker GS, Atreya CE, Simko J, Nakakura EK, Bergsland EK, Donner DB, Shokat KM, Warren RS. Effect of PIK3CA and KRAS mutations on sensitivity to ATP-competitive mTOR inhibitors in a primary xenograft model of colorectal carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 483. PMID 27982970 DOI: 10.1200/Jco.2012.30.4_Suppl.483 |
0.72 |
|
| 2012 |
Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Investigational New Drugs. 30: 2219-25. PMID 22270257 DOI: 10.1007/S10637-012-9793-Y |
0.713 |
|
| 2012 |
Ducker GS, Atreya CE, Shokat KM, Warren RS. Abstract PR4: Incomplete inhibition of phosphorylation of 4EBP1 is a mechanism for KRAS driven resistance to the ATP-competitive mTOR inhibitor PP242 in colorectal cancer Clinical Cancer Research. 18: PR4-PR4. DOI: 10.1158/1078-0432.Mechres-Pr4 |
0.733 |
|
| Show low-probability matches. |